Robert Jones, MD, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses exciting genitourinary cancer trial data from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. He highlights the KEYNOTE-057 (NCT02625961) trial looking at the efficacy of pembrolizumab in high-risk non-muscle-invasive bladder cancer that is unresponsive to BCG; the TRITON2 trial (NCT02952534) of the PARP inhibitor rucaparib in metastatic castration resistant prostate cancer; and the JAVELIN Renal 101 study (NCT02684006) investigating avelumab plus axitinib for advanced renal cell cancer.

свернуть